MSC Expansion — hPL vs FBS

The evidence base comparing human platelet lysate (hPL) and FBS for mesenchymal stem cell (MSC) expansion has grown substantially over the past decade. The conclusion is remarkably consistent across studies, cell sources, and laboratories: hPL at 5% outperforms FBS at 10% for MSC proliferation rate, and produces MSCs with equivalent or superior immunomodulatory potency. This post summarises the key data and explains the biology behind it.

Why MSC expansion medium matters

MSCs for clinical use must meet the ISCT (International Society for Cell Therapy) criteria for MSC identity — plastic adherence, specific surface marker expression (CD73+, CD90+, CD105+; CD34−, CD45−, CD14−, HLA-DR−), and tri-lineage differentiation potential. Beyond identity, clinical MSC products must demonstrate potency — the ability to suppress T cell proliferation and modulate macrophage polarisation, which is the primary therapeutic mechanism in GvHD, Crohn’s disease, and other inflammatory indications.

The choice of expansion medium directly affects both the efficiency of manufacturing (expansion fold, population doubling time) and the quality of the product (potency markers, phenotype stability, exhaustion status). A medium that drives fast expansion at the cost of reduced potency is counterproductive.

Proliferation — the consistent finding

Across more than 30 published comparative studies of hPL vs. FBS for MSC expansion (bone marrow, adipose, umbilical cord, Wharton’s Jelly sources), the proliferation data is highly consistent:

The faster proliferation in hPL is primarily driven by higher concentrations of human PDGF-AB and PDGF-BB — the primary MSC mitogens — released from platelet alpha granules. PDGF receptor signalling (PDGFRα/β) drives MSC proliferation through the PI3K/Akt and MAPK/ERK pathways. Human PDGF signals more efficiently through human PDGFRs than bovine PDGF in FBS — explaining the consistent proliferation advantage across MSC sources and laboratories.

ISCT criteria — phenotype stability

A critical concern when changing expansion medium is whether MSCs maintain their identity criteria. Published data consistently shows that hPL-expanded MSCs maintain ISCT surface marker criteria (CD73+, CD90+, CD105+; lineage negative) equivalently to FBS-expanded MSCs at the same passage number. No published study has reported loss of ISCT identity criteria in hPL-expanded MSCs compared to FBS.

Importantly, hPL-expanded MSCs at P5 show equivalent or better marker stability than FBS-expanded MSCs at P8 — because fewer passages are required to reach the same expansion fold, reducing the cumulative replicative stress on the cells.

Immunomodulatory potency — the key clinical attribute

MSC therapeutic mechanism is primarily paracrine — secretion of prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), TGF-β, IL-10, and HGF that suppress T cell proliferation and polarise macrophages toward an anti-inflammatory M2 phenotype. Potency is measured by T cell suppression assay (co-culture of MSCs with stimulated PBMCs, measuring CFSE dilution or ³H-thymidine incorporation) and by IDO activity (kynurenine assay).

Lot-to-lot variability — the underappreciated advantage of hPL

FBS lot-to-lot variability is well-documented and requires extensive lot qualification before each new FBS lot is introduced into a clinical MSC manufacturing process. A new FBS lot that fails MSC potency or expansion qualification can halt production for weeks while an alternative lot is sourced and qualified.

hPL from a large pooled donor population (typically 40–80 donors per lot) has significantly lower lot-to-lot variability in growth factor composition compared to FBS — because pooling averages out individual platelet donor variability. Published head-to-head comparisons of hPL lot variability show 2–3× lower coefficient of variation for MSC expansion rate between hPL lots compared to FBS lots from the same supplier.

Regulatory pathway — why hPL is now the preferred choice for clinical MSC

EMA Advanced Therapy Guidelines, FDA Guidance for ATMP manufacturing, and the International Pharmaceutical Excipients Council (IPEC) all encourage elimination of animal-derived components from ATMP manufacturing. For clinical MSC products, hPL provides:

• Xeno-free compliance: no bovine components — eliminates TSE/BSE documentation burden
• Human-derived material: collected from screened donors with IRB clearance — acceptable under EMA ATMP guidelines as a human-origin raw material
• GMP-grade availability: GMP hPL with full batch manufacturing records, donor documentation, viral testing, and sterility testing is available from qualified suppliers
• Reduced immunogenic risk: no residual bovine proteins on the MSC surface after expansion — reducing theoretical risk of xenogenic immune response in the patient

Practical considerations for switching from FBS to hPL

Fibrinogen management: Add heparin at 2 IU/mL to hPL-containing medium to prevent fibrin gel formation. Alternatively, use fibrinogen-depleted hPL. This is the most common technical issue encountered during the FBS-to-hPL transition and is easily solved.

Concentration: Start with 5% hPL. Some protocols use 7.5–10% hPL for the first passage from a fresh biopsy, then reduce to 5% for subsequent passages. Higher concentrations rarely improve expansion beyond 5% for most MSC sources.

Seeding density: hPL-expanded MSCs reach confluency faster — adjust seeding density downward by 20–30% or shorten passage intervals when switching from FBS to hPL to avoid over-confluence.

Lot qualification: hPL lots still require qualification before clinical use — but the qualification panel is simpler than FBS because there are no bovine-specific markers to test. Essential qualification tests: sterility, mycoplasma (PCR), HIV/HBV/HCV NAT, endotoxin (LAL), total protein, MSC expansion performance test on a reference MSC line.